AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30057048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 27098820 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise implementation administered and monitored in a quarterly rheumatological nurse‐administered set‐up targeting hyperlipidaemia, hypertension, hyperglycaemia, and microalbuminuria
Number of subjects: 300
Study 27098820 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment administered and monitored by general practitioner according to national guidelines
Number of subjects: 300
Study 24490888 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt enriched with alpha‐lactalbumin, casein tripeptides and B vitamins
Number of subjects: 67
Study 22569236 — intervention group
Group type: EXPERIMENTAL
Intervention: VLCD+E (Very Low-Calorie Diet + Exercise)
Number of subjects: 27
Study 22569236 — intervention group
Group type: COMPARATOR
Intervention: VLCD-only (Very Low-Calorie Diet only)
Number of subjects: 27
Study 19079825 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional over-involvement (EOI)
Number of subjects: 63
Study 19079825 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical comments (CC)
Number of subjects: 63
Study 19079825 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Emotional over-involvement (EOI)
Number of subjects: 63
Study 19079825 — intervention group
Group type: EXPERIMENTAL
Intervention: Family burden of care at follow-up
Number of subjects: 63
Study 19079825 — intervention group
Group type: EXPERIMENTAL
Intervention: Carers' critical comments (CC) at follow-up
Number of subjects: 63
Study 18823658 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg once a day, increased to 32 mg once a day after one month
Number of subjects: 1905
Study 18823658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1905
Study 18823658 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 1905
Study 15824508 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (5 doses of 200 mg weekly)
Number of subjects: 96
Study 15824508 — intervention group
Group type: COMPARATOR
Intervention: Oral FeSO4 (325 mg t.i.d.)
Number of subjects: 96
Study 12575874 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Appearance Motion Model (AAMM)
Number of subjects: 129
Study 12575874 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear intensity normalization
Number of subjects: 129
Study 10383527 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.d. in H. pylori-negative patients
Number of subjects: 58
Study 10383527 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.d. in H. pylori-positive patients
Number of subjects: 58
Study 10383527 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.d. in H. pylori-negative patients
Number of subjects: 58
Study 10383527 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.d. in H. pylori-positive patients
Number of subjects: 58
Study 8944109 — intervention group
Group type: EXPERIMENTAL
Intervention: Slit-lamp supported biometry
Number of subjects: 32
Study 8944109 — intervention group
Group type: COMPARATOR
Intervention: Hand-held biometry
Number of subjects: 32
Study 1683355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ribavirin therapy (loading dose of 33 mg/kg, 16 mg/kg every 6 h for 4 days, and 8 mg/kg every 8 h for 3 days)
Number of subjects: 242
Study 1683355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 1683355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ribavirin therapy
Number of subjects: 242
Study 6753092 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide (topical corticosteroid)
Number of subjects: 22
Study 6753092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30222087 — intervention group
Group type: EXPERIMENTAL
Intervention: X:IT intervention
Number of subjects: 3269
Study 30222087 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 3269
Study 29410968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TXA (1 g TXA intravenously)
Number of subjects: 93
Study 29410968 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical TXA (3 g TXA in 100 ml saline intra-articularly)
Number of subjects: 93
Study 29410968 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline both intravenously and intra-articularly)
Number of subjects: 93
Study 29410968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TXA vs Topical TXA
Number of subjects: 93
Study 25544738 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine treatment for 12 weeks
Number of subjects: 70
Study 25544738 — intervention group
Group type: COMPARATOR
Intervention: Dose-escalation intervention after 6 weeks
Number of subjects: 70
Study 24550216 — intervention group
Group type: EXPERIMENTAL
Intervention: GCK‐MODY diagnosis in women with fasting glucose ≥5.1 mmol/L
Number of subjects: 247
Study 24550216 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical criteria for differentiating GCK‐MODY from GDM
Number of subjects: 247
Study 24550216 — intervention group
Group type: COMPARATOR
Intervention: Population prevalence of GDM
Number of subjects: 247
Study 22779287 — intervention group
Group type: EXPERIMENTAL
Intervention: sugar‐free stick gum (Wrigley's Extra Freshmint)
Number of subjects: 42
Study 22779287 — intervention group
Group type: EXPERIMENTAL
Intervention: sugar‐free pellet gum (Wrigley's Extra Fruit)
Number of subjects: 42
Study 22779287 — intervention group
Group type: COMPARATOR
Intervention: no‐gum chewing
Number of subjects: 42
Study 19023614 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y (RY) reconstruction
Number of subjects: 70
Study 19023614 — intervention group
Group type: COMPARATOR
Intervention: rho-shaped Roux-en-Y (rRY) reconstruction
Number of subjects: 70
Study 17879532 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaihu Taoren Decoction (CTD)
Number of subjects: 119
Study 17879532 — intervention group
Group type: COMPARATOR
Intervention: Control group (TT homozygote)
Number of subjects: 119
Study 15536655 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared (NIR) spectroscopy
Number of subjects: 28
Study 15536655 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler perfusion imaging
Number of subjects: 28
Study 15536655 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital photography
Number of subjects: 28
Study 15536655 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all three techniques (NIR, Laser Doppler, Digital photography)
Number of subjects: 28
Study 12559479 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal Systems Behavior Scale (FrSBe)
Number of subjects: 131
Study 9521168 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (50 mg)
Number of subjects: 29133
Study 9521168 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg)
Number of subjects: 29133
Study 9521168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29133
Study 8120705 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 125
Study 8120705 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 125
Study 2757878 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting propranolol 160 mg
Number of subjects: 12
Study 2757878 — intervention group
Group type: COMPARATOR
Intervention: Long acting propranolol 80 mg
Number of subjects: 12
Study 7362091 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine nebulization at approximately 0.075 mg/kg
Number of subjects: 10
Study 7362091 — intervention group
Group type: COMPARATOR
Intervention: Isoetharine nebulization
Number of subjects: 10
Study 31306433 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for soil-transmitted helminth infection (specific interventions not detailed in the abstract)
Number of subjects: 434
Study 31306433 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without soil-transmitted helminth infection)
Number of subjects: 434
Study 28635026 — intervention group
Group type: EXPERIMENTAL
Intervention: ixekizumab 80 mg every 4 weeks (IXEQ4W)
Number of subjects: 33
Study 28635026 — intervention group
Group type: EXPERIMENTAL
Intervention: ixekizumab 80 mg every 12 weeks (IXEQ12W)
Number of subjects: 33
Study 28635026 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study 28635026 — intervention group
Group type: EXPERIMENTAL
Intervention: ixekizumab (any dosage)
Number of subjects: 33
Study 28635026 — intervention group
Group type: EXPERIMENTAL
Intervention: ixekizumab (IXEQ12W, IXEQ4W)
Number of subjects: 33
Study 25972257 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest dietary riboflavin intake
Number of subjects: 3115
Study 25972257 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest dietary B12 intake
Number of subjects: 3115
Study 25972257 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest dietary B6 intake
Number of subjects: 3115
Study 25972257 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest dietary intake levels of niacin and B12
Number of subjects: 3115
Study 25972257 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest dietary folate intake
Number of subjects: 3115
Study 25972257 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein plus zeaxanthin intake
Number of subjects: 3115
Study 23375005 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (isometric training of abdominal muscles, diaphragmatic breathing exercises, and abdominal massage during 12 40‐min sessions twice a week) + laxatives
Number of subjects: 0
Study 23375005 — intervention group
Group type: COMPARATOR
Intervention: Medication (laxatives only)
Number of subjects: 0
Study 21284545 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous PRF and OFD
Number of subjects: 18
Study 21284545 — intervention group
Group type: COMPARATOR
Intervention: OFD
Number of subjects: 18
Study 18678578 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV2‐TNFR:Fc (1 x 10(10) DNase resistant particles per ml joint volume)
Number of subjects: 15
Study 18678578 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV2‐TNFR:Fc (1 x 10(11) DNase resistant particles per ml joint volume)
Number of subjects: 15
Study 18678578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17341245 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to high disease severity score
Number of subjects: 353
Study 17341245 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of pneumonia (confirmed by chest radiograph)
Number of subjects: 353
Study 17341245 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen saturation (<90%)
Number of subjects: 353
Study 17341245 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of congestive heart failure
Number of subjects: 353
Study 17341245 — intervention group
Group type: EXPERIMENTAL
Intervention: Receipt of pneumococcal vaccine
Number of subjects: 353
Study 17341245 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater functional independence
Number of subjects: 353
Study 16813906 — intervention group
Group type: EXPERIMENTAL
Intervention: Overactive bladder questionnaire (OBQ) symptom bother subscale
Number of subjects: 2
Study 16813906 — intervention group
Group type: EXPERIMENTAL
Intervention: Overactive bladder questionnaire (OBQ) health related quality of life subscales (coping, concern, sleep, social interaction)
Number of subjects: 2
Study 16813906 — intervention group
Group type: COMPARATOR
Intervention: Change scores in patients perceiving no and little benefit
Number of subjects: 2
Study 16813906 — intervention group
Group type: EXPERIMENTAL
Intervention: Micturition diary variables
Number of subjects: 2
Study 12728754 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized education about proper foot care
Number of subjects: 40
Study 12728754 — intervention group
Group type: COMPARATOR
Intervention: Routine home care services (Control)
Number of subjects: 40
Study 10336577 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevidipine at target dose rates ranging from 0.12 to 48 nmol min‐1 kg‐1
Number of subjects: 25
Study 8760089 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile GH delivery (10.7 ng.kg‐1.min‐1 for men, 15 ng.kg‐1.min‐1 for women, 60 min peak width, 15 min peak width at half-height)
Number of subjects: 8
Study 8760089 — intervention group
Group type: COMPARATOR
Intervention: Constant GH infusion
Number of subjects: 8
Study 8760089 — intervention group
Group type: COMPARATOR
Intervention: GH deficiency
Number of subjects: 8
Study 1744358 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT) for 3 and 4 years
Number of subjects: 25
Study 1744358 — intervention group
Group type: COMPARATOR
Intervention: Non-immunotherapy (non-IT)
Number of subjects: 25
Study 1744358 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT)
Number of subjects: 25
Study 6125103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 102
Study 6125103 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 102
Study 6125103 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 102
Study 29587831 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 400
Study 29587831 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 400
Study 27869715 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol-stabilized arginine silicate (ASI; Nitrosigine®) 1500 mg/day for 14 days
Number of subjects: 0
Study 27869715 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol-stabilized arginine silicate (ASI; Nitrosigine®) 1500 mg/day for 3 days
Number of subjects: 0
Study 27869715 — intervention group
Group type: COMPARATOR
Intervention: Inositol-stabilized arginine silicate (ASI; Nitrosigine®) 1500 mg/day for a 10-min period
Number of subjects: 0
Study 23764718 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine 100 mg
Number of subjects: 371
Study 23764718 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg
Number of subjects: 371
Study 23764718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study 22940462 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral anger expression in LBP patients
Number of subjects: 48
Study 22940462 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait anger-out in LBP patients
Number of subjects: 48
Study 22940462 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily anger expression in LBP patients
Number of subjects: 48
Study 22940462 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait anger suppression (anger-in) in LBP patients
Number of subjects: 48
Study 22940462 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait anger-out in individuals low in trait anger-out
Number of subjects: 48
Study 21189770 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) with bone graft
Number of subjects: 20
Study 21189770 — intervention group
Group type: COMPARATOR
Intervention: Bone graft alone (control group)
Number of subjects: 20
Study 18364319 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based nutrition (EBN) interventions
Number of subjects: 0
Study 15776331 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO (10% glucose, 30 mmol . l (‐1) NaCl)
Number of subjects: 8
Study 15776331 — intervention group
Group type: COMPARATOR
Intervention: W (water, 30 mmol . l (‐1) NaCl)
Number of subjects: 8
Study 15776331 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 8
Study 15776331 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion
Number of subjects: 8
Study 11952072 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Number of subjects: 30
Study 11952072 — intervention group
Group type: COMPARATOR
Intervention: Rectal diazepam
Number of subjects: 30
Study 10622193 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphygmomanometer cuff pressures (diastolic pressure - 30 mm Hg to diastolic pressure + 5 mm Hg)
Number of subjects: 0
Study 7851585 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 30
Study 7851585 — intervention group
Group type: COMPARATOR
Intervention: Control (normal ovarian cycles)
Number of subjects: 30
Study 1781807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil plus N-acetylcysteine (1000 mg cefadroxil + 200 mg N-acetylcysteine)
Number of subjects: 12
Study 1781807 — intervention group
Group type: COMPARATOR
Intervention: Cefadroxil alone (1000 mg)
Number of subjects: 12
Study 6982626 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone (3.0 mg/kg)
Number of subjects: 46
Study 6982626 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.3 mg/kg)
Number of subjects: 46
Study 6982626 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin (0.07 ml/kg)
Number of subjects: 46
Study 6982626 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1.5 mg/kg)
Number of subjects: 46
Study 6982626 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.15 mg/kg)
Number of subjects: 46
Study 6982626 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (0.015 mg/kg)
Number of subjects: 46
Study 6982626 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.01 mg/kg) added to Althesin and Flunitrazepam
Number of subjects: 46
Study 6982626 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.01 mg/kg) added to Ketamine
Number of subjects: 46
Study 31629649 — intervention group
Group type: COMPARATOR
Intervention: Control (repeated initial vaccination with HBVaxPro 10 μg or Engerix‐B 20 μg)
Number of subjects: 480
Study 31629649 — intervention group
Group type: EXPERIMENTAL
Intervention: Twinrix 20 μg
Number of subjects: 480
Study 31629649 — intervention group
Group type: EXPERIMENTAL
Intervention: HBVaxPro 40 μg
Number of subjects: 480
Study 31629649 — intervention group
Group type: EXPERIMENTAL
Intervention: Fendrix 20 μg
Number of subjects: 480
Study 31506951 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomized trials in school health research
Number of subjects: 0
Study 28963290 — intervention group
Group type: EXPERIMENTAL
Intervention: So-Cheong-Ryong-Tang (SCRT)
Number of subjects: 156
Study 28963290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 25894667 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative cognitive‐affective therapy (ICAT)
Number of subjects: 80
Study 25894667 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced cognitive‐behavioral therapy (CBT‐E)
Number of subjects: 80
Study 22886490 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous pulsed dendritic cell vaccine
Number of subjects: 30
Study 22886490 — intervention group
Group type: COMPARATOR
Intervention: Supportive treatment
Number of subjects: 30
Study 20653487 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 IU vitamin D(3) plus vitamin E placebo (group D)
Number of subjects: 45
Study 20653487 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU synthetic all‐rac‐α‐tocopherol plus vitamin D placebo (group E)
Number of subjects: 45
Study 20653487 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 IU vitamin D(3) plus 600 IU synthetic all‐rac‐α‐tocopherol (group DE)
Number of subjects: 45
Study 20653487 — intervention group
Group type: COMPARATOR
Intervention: Vitamins D and E placebos (group P)
Number of subjects: 45
Study 19470928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation Program (CRP)
Number of subjects: 140
Study 19470928 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 140
Study 17446997 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 163
Study 17446997 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 163
Study 17446997 — intervention group
Group type: COMPARATOR
Intervention: Normotensive
Number of subjects: 163
Study 12585981 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study 12585981 — intervention group
Group type: COMPARATOR
Intervention: Traditional NSAIDs
Number of subjects: 0
Study 11908374 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Actibrush battery-powered toothbrush
Number of subjects: 110
Study 11908374 — intervention group
Group type: COMPARATOR
Intervention: Colgate Plus Diamond Head Toothbrush (manual)
Number of subjects: 110
Study 8737755 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Erythropoietin (IV EPO)
Number of subjects: 50
Study 8737755 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous Erythropoietin (SC EPO)
Number of subjects: 50
Study 1351025 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg once a day
Number of subjects: 125
Study 1351025 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 100 mg a day (50 mg twice a day)
Number of subjects: 125
Study 6741192 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily perseverance training of 60 min at about 50% VO2 max
Number of subjects: 144
Study 6741192 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 144
Study 30703172 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask continue group
Number of subjects: 175
Study 30703172 — intervention group
Group type: COMPARATOR
Intervention: Prong continue group
Number of subjects: 175
Study 30703172 — intervention group
Group type: COMPARATOR
Intervention: Rotation group
Number of subjects: 175
Study 30035399 — intervention group
Group type: EXPERIMENTAL
Intervention: Students with allergic diseases and a positive skin prick test (SPT)
Number of subjects: 1373
Study 30035399 — intervention group
Group type: EXPERIMENTAL
Intervention: Students with allergic disease who were SPT negative
Number of subjects: 1373
Study 30035399 — intervention group
Group type: COMPARATOR
Intervention: Control group (students with no allergic diseases)
Number of subjects: 1373
Study 25871403 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive support ventilation (ASV), a continuous weaning strategy
Number of subjects: 40
Study 25871403 — intervention group
Group type: COMPARATOR
Intervention: Biphasic positive airway pressure (BIPAP) with spontaneous breathing trials, a discontinuous technique
Number of subjects: 40
Study 23522095 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Disease Management (IDM)
Number of subjects: 1086